Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Drug-Drug Interaction Study of NS-025 With Triazolam in Healthy Japanese Male Subjects
jRCT2031240632Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Mar 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NS-025, sponsored by Nippon Shinyaku. Primary endpoints: Plasma concentrations of NS-025 and Plasma concentrations and pharmacokinetic parameters of triazolam. Started Mar 2025; status: completed.
02
Drugs
NS-025
Beyond the preview
Go deeper on jRCT2031240632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240632.